610 related articles for article (PubMed ID: 31695765)
21. Characterization of fragment sizes, copy number aberrations and 4-mer end motifs in cell-free DNA of hepatocellular carcinoma for enhanced liquid biopsy-based cancer detection.
Jin C; Liu X; Zheng W; Su L; Liu Y; Guo X; Gu X; Li H; Xu B; Wang G; Yu J; Zhang Q; Bao D; Wan S; Xu F; Lai X; Liu J; Xing J
Mol Oncol; 2021 Sep; 15(9):2377-2389. PubMed ID: 34133846
[TBL] [Abstract][Full Text] [Related]
22. The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients.
Zheng B; Liu XL; Fan R; Bai J; Wen H; Du LT; Jiang GQ; Wang CY; Fan XT; Ye YN; Qian YS; Wang YC; Liu GJ; Deng GH; Shen F; Hu HP; Wang H; Zhang QZ; Ru LL; Zhang J; Gao YH; Xia J; Yan HD; Liang MF; Yu YL; Sun FM; Gao YJ; Sun J; Zhong CX; Wang Y; Kong F; Chen JM; Zheng D; Yang Y; Wang CX; Wu L; Hou JL; Liu JF; Wang HY; Chen L
Clin Cancer Res; 2021 Jul; 27(13):3772-3783. PubMed ID: 33947693
[TBL] [Abstract][Full Text] [Related]
23. Plasma cell free DNA methylation markers for hepatocellular carcinoma surveillance in patients with cirrhosis: a case control study.
Lewin J; Kottwitz D; Aoyama J; deVos T; Garces J; Hasinger O; Kasielke S; Knaust F; Rathi P; Rausch S; Weiss G; Zipprich A; Mena E; Fong TL
BMC Gastroenterol; 2021 Mar; 21(1):136. PubMed ID: 33765926
[TBL] [Abstract][Full Text] [Related]
24. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
25. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
[TBL] [Abstract][Full Text] [Related]
26. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
[TBL] [Abstract][Full Text] [Related]
27. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
[TBL] [Abstract][Full Text] [Related]
28. Discovery and validation of DNA hypomethylation biomarkers for liver cancer using HRM-specific probes.
Stefanska B; Bouzelmat A; Huang J; Suderman M; Hallett M; Han ZG; Al-Mahtab M; Akbar SM; Khan WA; Raqib R; Szyf M
PLoS One; 2013; 8(8):e68439. PubMed ID: 23950870
[TBL] [Abstract][Full Text] [Related]
29. Novel urine cell-free DNA methylation markers for hepatocellular carcinoma.
Lin SY; Xia W; Kim AK; Chen D; Schleyer S; Choi L; Wang Z; Hamilton JP; Luu H; Hann HW; Chang TT; Hu CT; Woodard A; Gade TP; Su YH
Sci Rep; 2023 Dec; 13(1):21585. PubMed ID: 38062093
[TBL] [Abstract][Full Text] [Related]
30. Early detection and prognosis evaluation for hepatocellular carcinoma by circulating tumour DNA methylation: A multicentre cohort study.
Guo DZ; Huang A; Wang YC; Zhou S; Wang H; Xing XL; Zhang SY; Cheng JW; Xie KH; Yang QC; Ma CC; Li Q; Chen Y; Su ZX; Fan J; Liu R; Liu XL; Zhou J; Yang XR
Clin Transl Med; 2024 May; 14(5):e1652. PubMed ID: 38741204
[TBL] [Abstract][Full Text] [Related]
31. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
[TBL] [Abstract][Full Text] [Related]
32. Targeted deep sequencing of plasma circulating cell-free DNA reveals Vimentin and Fibulin 1 as potential epigenetic biomarkers for hepatocellular carcinoma.
Holmila R; Sklias A; Muller DC; Degli Esposti D; Guilloreau P; Mckay J; Sangrajrang S; Srivatanakul P; Hainaut P; Merle P; Herceg Z; Nogueira da Costa A
PLoS One; 2017; 12(3):e0174265. PubMed ID: 28333958
[TBL] [Abstract][Full Text] [Related]
33. Is Cell-Free DNA Testing in Hepatocellular Carcinoma Ready for Prime Time?
Jeepalyam S; Sheel A; Ejaz A; Miller E; Manne A
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762533
[TBL] [Abstract][Full Text] [Related]
34. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
[TBL] [Abstract][Full Text] [Related]
35. Genome-Scale Methylation Analysis of Circulating Cell-Free DNA in Gastric Cancer Patients.
Ren J; Lu P; Zhou X; Liao Y; Liu X; Li J; Wang W; Wang J; Wen L; Fu W; Tang F
Clin Chem; 2022 Feb; 68(2):354-364. PubMed ID: 34791072
[TBL] [Abstract][Full Text] [Related]
36. Value of circulating cell-free DNA in diagnosis of hepatocelluar carcinoma.
Chen K; Zhang H; Zhang LN; Ju SQ; Qi J; Huang DF; Li F; Wei Q; Zhang J
World J Gastroenterol; 2013 May; 19(20):3143-9. PubMed ID: 23716996
[TBL] [Abstract][Full Text] [Related]
37. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery.
Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW
Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395
[No Abstract] [Full Text] [Related]
38. Circulating cell-free DNA-based epigenetic assay can detect early breast cancer.
Uehiro N; Sato F; Pu F; Tanaka S; Kawashima M; Kawaguchi K; Sugimoto M; Saji S; Toi M
Breast Cancer Res; 2016 Dec; 18(1):129. PubMed ID: 27993161
[TBL] [Abstract][Full Text] [Related]
39. Loci-specific differences in blood DNA methylation in HBV-negative populations at risk for hepatocellular carcinoma development.
Lubecka K; Flower K; Beetch M; Qiu J; Kurzava L; Buvala H; Ruhayel A; Gawrieh S; Liangpunsakul S; Gonzalez T; McCabe G; Chalasani N; Flanagan JM; Stefanska B
Epigenetics; 2018; 13(6):605-626. PubMed ID: 29927686
[TBL] [Abstract][Full Text] [Related]
40. Identification of DNA methylation signatures for hepatocellular carcinoma detection and microvascular invasion prediction.
Hao Y; Yang Q; He Q; Hu H; Weng Z; Su Z; Chen S; Peng S; Kuang M; Chen Z; Xu L
Eur J Med Res; 2022 Dec; 27(1):276. PubMed ID: 36464701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
